ATOPIC DERMATITIS / ECZEMA
CURRENTLY ENROLLING TRIALS
A Phase 2b, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of ATI-1777 in Patients 12 to 65 Years Old with Moderate or Severe Atopic Dermatitis (AD)
Open for participants age 12 to 65 with a clinical diagnosis of chronic moderate-to-severe Atopic Dermatitis with at least a 6-month history of AD.
Requirements:
-
AD affecting ≥ 5% Body Surface Area (BSA), or at least 5 hand prints (1 hand print = 1%)
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study with Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects with Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)
Open for participants ages 12 to 18 with a clinical diagnosis of chronic moderate-to-severe Atopic Dermatitis that has been documented for at least 6 months.
Requirements:
-
Recent history (within 6 months of screening) of inadequate response to topical corticosteroids (TCS) of medium or higher potency, or for whom topical treatments are otherwise medically inadvisable.
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multicenter Phase 2a Study to Investigate Efficacy and Safety of Zabedosertib (BAY 1834845) for the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
Open for participants ages 18 to 65 with chronic moderate-to-severe Atopic Dermatitis that has been documented for at least 1 year.
Requirements:
-
Recent history (within 6 months of screening) of inadequate response to treatment with topical corticosteroids, or for whom topical treatments are otherwise medically inadvisable.
-
​
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
UPCOMING CLINICAL TRIALS
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects with Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)
Open for participants age ≥ 18 with a clinical diagnosis of chronic moderate-to-severe Atopic Dermatitis that has been documented for at least 6 months.
Requirements:
-
Recent history (within 6 months of screening) of inadequate response to topical corticosteroids (TCS) of medium or higher potency, or for whom topical treatments are otherwise medically inadvisable.
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
A Phase 2/3, Two-Part Study to Evaluate the Efficacy and Long-Term Safety with Oral Etrasimod, 2 mg, Once Daily in Adult Participants with Moderate-to-Severe Atopic Dermatitis with a History of Prior Systemic Treatment Failure
Open for participants age ≥ 18 with a clinical diagnosis of chronic moderate-to-severe Atopic Dermatitis that has been documented for at least 1 year.
Requirements:
-
Must have failed a prior systemic therapy for AD (refractory, moderate-to-severe AD that is not adequately controlled with other systemic drug products), or when use of those therapies is inadvisable.
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab
Open for participants age ≥ 12 with a clinical diagnosis of chronic moderate-to-severe Atopic Dermatitis
Requirements:
-
Must have been previously treated with dupilumab
Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.
Don't qualify for any of our trials?
We begin new trials often. If you do not qualify for our current studies, please leave your information, and we'll keep you updated of any upcoming trials that may be right for you.